Stocks making the biggest moves premarket: Pfizer, Apple, Palantir, Zebra Technologies & more

Premarket moves were mixed: Revvity rose 7% after raising full-year adjusted EPS guidance to $5.40–$5.45, while Apple fell nearly 4% on a disappointing margin forecast and weaker-than-expected iPad sales. Pfizer beat Q3 EPS and revenue estimates, and Yum Brands beat adjusted EPS expectations; Zebra and Gartner each dropped over 6% despite beating Q3 estimates. Palantir fell nearly 8% even as U.S. commercial revenue jumped 148% to $984 million and it projected about $2.65 billion in Q4 revenue and $8.53 billion for full-year 2026.

Analysis

The useful signal is the dispersion between reported beats and share reactions: near-term earnings are being discounted when investors see weaker cash conversion, margin visibility, or a high bar for execution. That makes guidance quality—not the headline EPS surprise—the key 1–3 month catalyst. ZBRA’s modest FCF-guide shortfall may be more consequential than its quarterly beat if working-capital or cash-conversion trends weaken; verify those drivers before treating the selloff as an overreaction. For AAPL, the margin outlook is a broader earnings-quality risk than the iPad miss alone, but the article gives no detail on the source or duration of pressure. PLTR’s reaction despite strong commercial growth is a warning that growth may already be heavily reflected in expectations; it is not, by itself, evidence that demand is deteriorating. IT’s selloff despite improved guidance likewise suggests the market wants stronger forward indicators, not just a higher annual outlook. Over 6–18 months, the differentiator will be whether guidance converts into durable cash generation and repeatable demand. The contrarian opportunity is selective: some negative reactions may overshoot, but buying beats indiscriminately is poorly supported here.

Key Decisions for Investors

• AAPL: Avoid adding on the first premarket dip. Consider a defined-risk, near-dated put spread only if post-open trading confirms weakness and management’s margin explanation points to persistent pressure; cap risk at premium paid. Reassess if margins stabilize in subsequent guidance or the selloff reverses and holds.
• ZBRA: Treat as a watch, not an automatic short. If shares fail to reclaim the post-earnings breakdown after the open, a tactical short is reasonable with risk limited above the post-earnings high; cover if cash-conversion commentary or later FCF updates show the shortfall was timing-related. Verify working capital and cash-flow components first.
• RVTY: Do not chase the sharp premarket move. A pullback that holds while the raised EPS range remains intact offers a better entry; trim or exit if later updates fail to support the guidance increase with demand and operating performance.
• PLTR and IT: Avoid buying either solely because results beat or guidance improved. Monitor the next 1–3 months for evidence that forward demand indicators sustain the optimism; stabilization after the initial selloff would argue the reset was positioning-driven, while continued weakness alongside softer guidance would validate a lower expectations baseline.